Marks Group Wealth Management Inc Raises Stock Position in Becton, Dickinson and Company $BDX

Key Points

• Marks Group Wealth Management Inc increased its stake in Becton, Dickinson and Company by 32.4% in the second quarter, now owning a total of 57,117 shares valued at approximately $9.8 million.
• Multiple institutional investors have also increased their holdings in Becton, Dickinson, with Brighton Jones LLC rising its position by 98.2% in the fourth quarter, reflecting confidence in the company.
• Becton, Dickinson reported a strong earnings quarter with $3.68 earnings per share, surpassing estimates, and generated $5.51 billion in revenue, up 10.4% year-over-year.

Marks Group Wealth Management Inc boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 32.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 57,117 shares of the medical instruments supplier's stock after buying an additional 13,988 shares during the quarter. Becton, Dickinson and Company makes up 0.9% of Marks Group Wealth Management Inc's holdings, making the stock its 21st biggest position. Marks Group Wealth Management Inc's holdings in Becton, Dickinson and Company were worth $9,838,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its position in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after buying an additional 877 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in Becton, Dickinson and Company by 50.6% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier's stock valued at $18,808,000 after buying an additional 27,581 shares during the period. FORA Capital LLC acquired a new stake in Becton, Dickinson and Company during the first quarter valued at $3,458,000. Foster Victor Wealth Advisors LLC acquired a new stake in Becton, Dickinson and Company during the first quarter valued at $6,406,000. Finally, GAMMA Investing LLC grew its position in Becton, Dickinson and Company by 29.9% during the first quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier's stock valued at $744,000 after buying an additional 748 shares during the period. Institutional investors and hedge funds own 86.97% of the company's stock.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $193.67 on Monday. The company's 50-day moving average price is $189.03 and its 200-day moving average price is $187.06. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The company has a market cap of $55.51 billion, a P/E ratio of 34.83, a P/E/G ratio of 1.51 and a beta of 0.25. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping the consensus estimate of $3.40 by $0.28. The firm had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company's revenue for the quarter was up 10.4% on a year-over-year basis. During the same period last year, the firm posted $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were paid a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 74.82%.

Insider Activity

In other news, Director Claire Fraser sold 917 shares of the firm's stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director directly owned 22,226 shares of the company's stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 3,023 shares of company stock worth $562,036. Insiders own 0.36% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on BDX. Argus raised their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Becton, Dickinson and Company in a research report on Saturday, September 27th. Wells Fargo & Company lifted their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research report on Friday, August 8th. Royal Bank Of Canada initiated coverage on shares of Becton, Dickinson and Company in a research report on Thursday, September 25th. They issued a "sector perform" rating and a $211.00 target price on the stock. Finally, Wall Street Zen upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Three research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $205.40.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.